Novo Nordisk Fights Back: Battle Over Unapproved Semaglutide Compounds in South Africa

Novo Nordisk is taking legal action in South Africa to stop the sale of unapproved semaglutide compounds by iDexis, citing patient safety concerns. While Novo argues that these products bypass regulations, iDexis disputes the claims. The case reflects broader efforts to regulate GLP-1 drug versions worldwide.

Novo Nordisk, a Danish pharmaceutical giant, has sought legal intervention in South Africa to halt the distribution of unauthorized versions of its semaglutide-based drugs for weight loss and diabetes. The company has filed an application in the South African High Court against iDexis, a local compounding pharmacy accused of making and selling these products without regulatory approval.

The core of the case lies in patient safety, product integrity, and regulatory compliance. Compounding, which involves customizing medication for individual patients, is heavily regulated in South Africa, prohibiting large-scale production of unregistered drugs. The dispute centers on iDexis's version of semaglutide and whether it matches the approved formulation used by Novo Nordisk.

This South African lawsuit echoes Novo Nordisk's similar battles elsewhere, including in the United States, to curb the unauthorized sale of GLP-1 drugs. These products have gained popularity due to their efficacy in diabetes management and weight loss, creating a grey market due to high demand and pricing challenges.